… Using hepatocellular carcinoma (HCC) as a model, we … NAC) and glutathione (GSH) on
tumor formation and growth. … Sorafenib treatment in vivo using the orthotopic liver injection …

… with the EGFR inhibitor, erlotinib, in patients with unresectable or metastatic disease (26–29). …
Similarly, a study using the multitargeted kinase inhibitor sorafenib was published that …

… Erlotinib can prevent activation of Akt signaling pathway. The median OS was 8.55 months in
both the bevacizumab and erlotinib combination and sorafenib … and sorafenib monotherapy …

… Several animal models examining the hypoxic tumor microenvironment in HCC with small
fiberoptic sensors or radiographic imaging … Sorafenib in advanced hepatocellular carcinoma …

… 1.6 Reversible sorafenib resistance in an orthotopic model of hepatocellular carcinoma..........…
Many of the approved molecular targeted therapies such as cetuximab and erlotinib (EGFR-…

… tor of EGFR, erlotinib, on liver cancer in an orthotopic rat model of HCC showed no antitumor
effect.These unsuccessful trials and negative results in animal models called into question …

… erlotinib to sorafenib did not produce additive or synergistic effects in vitro or in vivo (51). A
phase I study that evaluated sorafenib and erlotinib … to develop preclinical animal models that …

… This study failed to reach its primary endpoint, with a similar median OS in the sorafenib plus
erlotinib and sorafenib plus placebo groups (9.5 versus 8.5 months, respectively; HR 0.929; …

… Hepatocellular carcinoma (HCC) is the second most common cause of cancerrelated … of
Sorafenib with AKT inhibitor compared to untreated control and to standard treatment, Sorafenib, …

… of erlotinib and sorafenib compared to sorafenib and placebo … mTOR inhibition in a rat model
of hepatocellular carcinoma. J … -tumor activity of sorafenib in ectopic and orthotopic models …